Clinical potential of midostaurin in advanced systemic mastocytosis
Marie Olivia Chandesris,1–3 Gandhi Damaj,1,4 Olivier Lortholary,1,3,5 Olivier Hermine1–3,6 On behalf of the CEREMAST study group 1French Reference Center for Mastocytosis (CEREMAST), 2Department of Hematology, Necker Children’s Hospital, APHP, 3Sorbonne Paris Cit&ea...
Guardado en:
Autores principales: | Chandesris MO, Damaj G, Lortholary O, Hermine O |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a639a5e68fd447ebb276c6b6831a5a80 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
por: Carrà G, et al.
Publicado: (2019) -
Blood and Lymphatic Cancer: Targets and Therapy
Publicado: (2012) -
Novel approaches to treating advanced systemic mastocytosis
por: Gilreath JA, et al.
Publicado: (2019) -
Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo J, et al.
Publicado: (2016) -
Advances in the diagnosis and management of lymphoma
por: Matasar MJ, et al.
Publicado: (2012)